Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients-Reference-Cited by-同舟云学术

Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients

Published:2002-07 Issue:1 Volume:118 Page:174-180
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Terpos Evangelos,Mougiou Athina,Kouraklis Alexandra,Chatzivassili Aria,Michalis Evridiki,Giannakoulas Nicholas,Manioudaki Eleni,Lazaridou Anna,Bakaloudi Vassiliki,Protopappa Maria,Liapi Dimitra,Grouzi Elisavet,Parharidou Agapi,Symeonidis Argyris,Kokkini Garoufalia,Laoutaris Nikolaos P.,Vaipoulos George,Anagnostopoulos Nikolaos I.,Christakis John I.,Meletis John,Bourantas Konstantinos L.,Zoumbos Nicholas C.,Yataganas Xenophon,Viniou for The Greek MDS Study Grou Nora-Athina

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.2002.03583.x/fullpdf

Reference29 articles.

1. In vitro study of erythropoiesis in patients with aplastic anemia and myelodysplastic syndromes: a possible tool for prospective determination of the clinical effectiveness of growth factors;Aoki;Hematological Pathology,1992

2. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes;Asano;Blood,1994

3. Proposals for the classification of the myelodysplastic syndromes;Bennett;British Journal of Haematology,1982

4. A patient-oriented approach to treatment of myelodysplastic syndromes;Cazzola;Haematologica,1998

5. Report of an international working group to standardize response criteria for myelodysplastic syndromes;Cheson;Blood,2000

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data;Turkish Journal of Hematology;2023-05-30

2. Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes;Journal of Clinical Medicine;2022-03-17

3. The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study;Indian Journal of Hematology and Blood Transfusion;2021-06-26

4. Luspatercept in the treatment of lower-risk myelodysplastic syndromes;Future Oncology;2021-04

5. Evolving therapies for lower-risk myelodysplastic syndromes;Annals of Hematology;2020-02-20